Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor

VENT-03 was safe and well-tolerated at all tested dose levels Favorable pharmacokinetic profile enables once-daily dosing Demonstrated full target inhibition Initiation of a Phase 2 trial with VENT-03 in patients with systemic lupus erythematosus (SLE) expected in 2025 WALTHAM, Mass. & MONTREAL — October 31, 2024 — (BUSINESS WIRE) — Ventus Therapeutics , a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and develop differentiated small-molecule therapeutics, today announced results from its Phase 1 clinical trial of VENT-03, the first cyclic GMP-AMP synthase (cGAS) inhibitor to successfully complete a first-in-human study. The Phase 1 trial evaluated the pharmacokinetics (PK), target engagement, safety, and tolerability of VENT-03 across a broad range of single and multiple ascending doses in 72 healthy adult volunteers. “The extraordinary profile demonstrated by this trial qualifies VENT-03 as a first- and best-in-class anti-cGAS medication and underscores the power of our ReSOLVE™ platform to develop high-quality small molecules for targets that have historically been undruggable,” said Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus. “These results unlock the path to exploring the broad potential of cGAS inhibition across a wide range of autoimmune disorders and cardiometabolic diseases, beginning with lupus. We’re excited to continue leading the way in cGAS development and look forward to initiating a Phase 2 trial with VENT-03 in SLE in 2025.” In the Phase 1 trial, VENT-03 was safe and well-tolerated at doses far exceeding those planned for use in Phase 2 trials. There were no dose-limiting or dose-related toxicities, serious adverse events, or changes in clinical laboratory parameters, electrocardiogram (ECG), or vital signs. All treatment-related adverse events were mild, transient, and easily managed. VENT-03 demonstrated a favorable PK profile that supports once-daily dosing. In addition, VENT-03 reached plasma concentrations required for full target inhibition and demonstrated robust pharmacodynamics. Ventus plans to present full data from the Phase 1 trial at a future medical conference. “Available treatments for lupus today include injectable medicines for the type I interferon or BAFF pathways that address only limited aspects of patients’ symptoms and disease course,” said Xavier Valencia, M.D., Head of Clinical Development at Ventus. “A once-daily oral cGAS inhibitor has the potential to modulate both pathways validated by biologics, impact multiple facets of SLE, and provide superior efficacy compared to existing treatments and therapies in development.” About cGAS cGAS is an intracellular pattern recognition receptor that is activated after binding to double-stranded DNA (dsDNA) in the cytoplasm. The presence of dsDNA in the cytoplasm is often the result of cellular dysfunction, which is a hallmark of many autoimmune and inflammatory diseases. Activation of cGAS leads to cGAMP formation, activation of STING, pronounced inflammation, and tissue damage. In both patients and preclinical models of disease, the cGAS pathway has been shown to be a key driver of lupus and other inflammatory diseases, such as systemic sclerosis, dermatomyositis, and Sjögren’s disease. About Ventus Therapeutics Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying deep protein science expertise and a proprietary computational chemistry platform to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders. Ventus’ ReSOLVE™ platform combines the latest advances in artificial intelligence/machine learning (AI/ML), structural biology, and biophysics to model the full spectrum of protein dynamics at an unparalleled resolution. Using ReSOLVE™, the company screened its first target in 2020, selected three development candidates in 2022, advanced its two wholly-owned product candidates into the clinic in 2023, and completed Phase 1 trials for both programs in 2024: VENT-03, a potent, selective, oral cGAS inhibitor, and VENT-02, a potent, brain-penetrant, oral NLRP3 inhibitor. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn . Contacts: Media Dan Budwick 1AB [email protected] Investors Steve Klass 1AB [email protected] © 2026 Ventus Therapeutics. All Rights Reserved. Explore About Pipeline Platform Patients News & Events Careers Viewpoints Contact For general inquiries - [email protected] For medical inquiries - [email protected] USA 100 Beaver St, Suite 201 Waltham, Massachusetts 02453 Canada 4800, rue Lévy # 110 Saint-Laurent, H4R 2P1, QC, Canada Follow Us Legal Privacy Policy Cookie Policy click click MENU About Overview Leadership Board of Directors Founders Advisors Investors Pipeline Pipeline VENT-03 VENT-02 VENT-04 Platform Patients News & Events Latest News Events Media Coverage Careers Overview Open Positions Viewpoints À propos Aperçu Direction Conseil d’administration Fondateurs Consultants Investisseurs Filiere de Developpement Filiere de Developpement VENT-03 VENT-02 VENT-04 Plateforme Essais cliniques Actualités et événements Dernières Nouvelles événements Dans les médias Emplois Aperçu Postes Vacants Points de vue We are using cookies to give you the best experience on our website. To find out more about the information we collect, please review our Privacy Policy . You can find out more about which cookies we are using or switch them off in settings . Nous utilisons des témoins pour vous offrir la meilleure expérience possible sur notre site Web. Pour en savoir plus sur les informations que nous recueillons, veuillez consulter notre Politique de confidentialité . Vous y trouverez de plus amples renseignements sur les témoins que nous utilisons, ou vous pouvez les désactiver dans les paramètres . Accept / Accepter Settings / Paramètres Close GDPR Cookie Settings Privacy Overview / Généralités sur la confidentialité Strictly Necessary Cookies / Témoins strictement nécessaires 3rd Party Cookies / Témoins tiers Powered by GDPR Cookie Compliance Privacy Overview / Généralités sur la confidentialité This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. To find out more about the information we collect, please review our Privacy Policy . Nous utilisons des témoins afin de vous offrir la meilleure expérience utilisateur possible sur notre site Web. Les informations contenues dans les fichiers témoins sont stockées dans votre navigateur. Elles servent entre autres à vous reconnaître lorsque vous revenez sur notre site Web et à nous aider à déterminer quelles sections du site vous intéressent le plus ou vous sont les plus utiles. Pour en savoir davantage sur les informations que nous recueillons, veuillez consulter notre Politique de confidentialité . Strictly Necessary Cookies / Témoins strictement nécessaires Strictly Necessary Cookies should be enabled at all times so that we can save your preferences for cookie settings. Les témoins strictement nécessaires doivent être activés en tout temps pour que vos préférences concernant les paramètres des témoins puissent être enregistrées. Enable or Disable Cookies Enabled Disabled 3rd Party Cookies / Témoins tiers This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website. Ce site Web utilise Google Analytics pour collecter des informations anonymes telles que le nombre de visiteurs sur le site et les pages les plus populaires. En maintenant ces témoins activés, vous nous aidez à améliorer notre site Web. Enable or Disable Cookies Enabled Disabled Enable All / Activer tout Reject All / Refuser tout Save Changes / Enregistrer les modifications

The release as fetched from its publisher. ventustx.com ↗